Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 834-840

  Wong, Man Yi ^a   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Liposomes; Quercetin; Trastuzumab; Vincristine

Indexed keywords

ANTI-TUMOR ACTIVITIES; BODY WEIGHT; BREAST CANCER; BREAST TUMOR; CIRCULATION TIME; CLINICAL APPLICATION; CLINICAL TREATMENTS; CO-ENCAPSULATION; DRUG RELEASE; HUMAN BREAST; IN-VIVO; MAXIMUM TOLERATED DOSE; MOLAR RATIO; QUERCETIN; SYNERGISTIC COMBINATIONS; TRASTUZUMAB; TUMOR GROWTH; VEHICLE CONTROL; VINCRISTINE;

ANIMALS; BIOLOGICAL MATERIALS; CONTROL SYSTEM SYNTHESIS; DISEASES; DRUG PRODUCTS; LIPOSOMES; MONOCLONAL ANTIBODIES; PHENOLS; PHOSPHOLIPIDS; TUMORS;

FATTY ACIDS;

LIPOSOME; QUERCETIN; TRASTUZUMAB; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, SCID; QUERCETIN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 82255193872     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.02.001     Document Type: Article

References (32)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Hennessy B.T., Pusztai L. Adjuvant therapy for breast cancer. Minerva Ginecol 2005, 57:305-326.
3. Dizdar O., Altundag K. Current and emerging treatment options in triple-negative breast cancer. Oncol Rev 2010, 4:5-13.
4. Chen J.Q., Russo J. ER-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta - Rev Cancer 2009, 1796:162-175.
5. Heinemann V. Definition of an optimal first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 2003, 81:43-48.
6. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13:238-252.
7. Zamboni W.C. Liposomal, Nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11:8230-8234.
8. Lee R.J. Liposomal delivery as a mechanism to enhance synergism between anticancer drugs. Mol Cancer Ther 2006, 5:1639-1640.
9. Allen T., Stuart D. Liposomal pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes. Liposomes: Rational design 1999, 63-67. Marcel Dekker, New York. A.S. Janoff (Ed.).
10. Maeda H. Enhanced permeability and retention (EPR) effect: basis for drug targeting to tumor. Biomedical aspects of drug targeting 2002, 211-228. Kluwer Academic Publishers, Norwell, MA. 1st ed. V. Muzykantov, V. Torchilin (Eds.).
11. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
12. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (BBA) - Biomembranes 2007, 1768:678-687.
13. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5:1854-1863.
14. Leslie E.M., Mao Q., Oleschuk C.J., Deeley R.G., Cole S.P.C. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 2001, 59:1171-1180.
15. Wong M.Y., Chiu G.N.C. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anti-Cancer Drugs 2010, 21:401-410.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
17. Chou T.C., Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977, 252:6438-6442.
18. Mayer L.D., Tai L.C., Bally M.B., Mitilenes G.N., Ginsberg R.S., Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990, 1025:143-151.
19. Fenske D.B., Wong K.F., Maurer E., Maurer N., Leenhouts J.M., Boman N., et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta (BBA) - Biomembranes 1998, 1414:188-204.
20. Waterhouse D.N., Madden T.D., Cullis P.R., Bally M.B., Mayer L.D., Webb M.S. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Liposomes, Part E. 2005, 40-57. Elsevier Academic Press, San Diego, CA. 1st ed. N. Düzgünes (Ed.).
21. Goniotaki M., Hatziantoniou S., Dimas K., Wagner M., Demetzos C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines. J Pharm Pharmacol 2004, 56:1217-1224.
22. Yang C.Y., Hsiu S.L., Wen K.C., Lin S.P., Tsai S.Y., Hou Y.C., et al. Bioavailability and metabolic pharmacokinetics of rutin and quercetin in rats. J Food Drug Anal 2005, 13:244-250.
23. Park K., de Oca G., Bonello P., Lee K.J., Dabrowski K. Determination of quercetin concentrations in fish tissues after feeding quercetin-containing diets. Aquacult Int 2009, 17:537-544.
24. Harasym T.O., Liboiron B.D., Mayer L.D. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol 2010, 596:291-323.
25. Harasym T.O., Tardi P.G., Johnstone S.A., Mayer L.D. Fixed drug ratio liposome formulations of combination cancer therapeutics. Liposome Technology 2007, 25-48. Informa Healthcare, New York. G. Gregoriadis (Ed.).
26. Laster W.R., Schabel F.M., Skipper H.E., Wilcox W.S., Thomson J.R. Experimental evaluation of potential anticancer agents. IV. Host weight loss as it relates to false positives in drug evaluation. Cancer Res 1961, 21:895-906.
27. Song X., Zhao Y., Hou S., Xu F., Zhao R., He J., et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008, 69:445-453.
28. Bissery M.C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-4852.
29. Horton J.K., Houghton P.J., Houghton J.A. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol 1988, 37:3995-4000.
30. Jackson D.V., Bender R.A. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res 1979, 39:4346-4349.
31. Corbett T.H., Polin L., Roberts B.J. Transplantable syngeneic rodent tumors: Solid tumors in mice. Tumor Models in Cancer Research 2002, 41-73. Humanapress.com, Totowa, NJ. 1st ed. B.A. Teicher (Ed.).
32. Krishna R., Webb M., St.Onge G., Mayer L.D. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 2001, 298:1206-1212.